{
    "clinical_study": {
        "@rank": "16674", 
        "acronym": "P27A", 
        "arm_group": [
            {
                "arm_group_label": "Alhydrogel", 
                "arm_group_type": "Experimental", 
                "description": "Alhydrogel (adjuvant)/P27A vaccine candidate arm involves two dosages of P27A antigen (10 and 50 microg)"
            }, 
            {
                "arm_group_label": "GLA-SE", 
                "arm_group_type": "Experimental", 
                "description": "GLA-SE as adjuvant/P27A vaccine candidate is tested in two dosages (2.5 and 5 microg) together with two dosages of the P27A antigen (10 and 50 microg)"
            }, 
            {
                "arm_group_label": "Control rabies vaccine Verorub TM", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Rabies vaccine will be administered in Phase IIb only to 8 Tanzanian volunteers in three injections"
            }
        ], 
        "brief_summary": {
            "textblock": "P27A study is designed as a randomized phase Ia/Ib trial to evaluate the safety and\n      immunogenicity of the blood stage candidate vaccine P27A against P. falciparum  -  P27A\n      antigen and associated adjuvant (Alhydrogel or GLA-SE) - in malaria non exposed European\n      volunteers(Switzerland; phase Ia) and malaria exposed African volunteers (Tanzania; phase\n      Ib)."
        }, 
        "brief_title": "Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Malaria", 
        "condition_browse": {
            "mesh_term": "Malaria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Phase Ia Inclusion criteria:\n\n               1. Healthy volunteers aged 18-45 years\n\n               2. General good health based on history and clinical examination\n\n               3. Written informed consent obtained before any study procedure\n\n               4. Female volunteers practicing contraception before and up to 13 weeks after the\n                  last immunisation\n\n               5. Available to participate in follow-up for the duration of study (34 weeks)\n\n               6. Reachable by phone during the whole study period\n\n          -  Phase Ib inclusion criteria\n\n               1. Healthy male volunteers aged 18-45 years\n\n               2. General good health based on history and clinical examination\n\n               3. Written informed consent obtained before any study procedure\n\n               4. Available to participate in follow-up for the duration of study (34 weeks)\n\n               5. Reachable by phone during the whole study period\n\n               6. Having always lived in an area of low malaria transmission\n\n        Exclusion Criteria:\n\n          -  Phase Ia Exclusion criteria:\n\n               1. Positive pregnancy test for females\n\n               2. Actively breast feeding females\n\n               3. Previous participation in any malaria vaccine trial\n\n               4. Symptoms, physical signs or laboratory values suggestive of systemic disorders,\n                  including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency,\n                  psychiatric and other conditions, which could interfere with the interpretation\n                  of the trial results or compromise the health of the volunteers\n\n               5. Any clinically significant laboratory abnormalities on screened blood samples\n                  beyond the normal range, as defined at the clinical trial site\n\n               6. Enrolment in any other clinical trial during the whole trial period\n\n               7. Intake of chronic medication, especially immunosuppressive agents (steroids,\n                  immunomodulating or immunosuppressive drugs) during the 13 weeks preceding the\n                  screening visit or during the trial period except topical  and inhaled steroids\n\n               8. Volunteers unable to be closely followed for social, geographic or psychological\n                  reasons\n\n               9. Previous history of drug or alcohol abuse interfering with normal social\n                  function during a period of one year prior to enrolment in the study\n\n              10. Known hypersensitivity to any of the vaccine components (adjuvant or peptide)\n\n              11. Vaccination or infusion of gammaglobulin from 4 weeks prior to the first\n                  vaccination and up to 6 weeks after the third vaccination\n\n              12. Any history of malaria\n\n              13. History of living in a malaria endemic area for more than five (5) years OR\n                  living in a malaria endemic area in early childhood. For practical purposes, all\n                  regions for which malaria chemoprophylaxis is advised by travel clinic are\n                  considered malaria endemic (cf. www.safetravel.ch).\n\n              14. Known exposure to malaria in the previous six (6) months, defined as a visit to\n                  a malaria endemic region\n\n              15. P27A ELISA positive OR parasite ELISA antibody positive AND Known exposure to\n                  malaria in a malaria endemic area\n\n              16. P27A ELISA positive AND parasite ELISA antibody positive (with or without\n                  history of stay in a malaria endemic area)\n\n              17. Intention to travel to malaria endemic countries during the study period\n\n              18. Positive HIV, HBV or HCV tests\n\n          -  Phase Ib exclusion criteria\n\n               1. Previously participated in any malaria vaccine trial\n\n               2. Symptoms, physical signs or laboratory values suggestive of systemic disorders,\n                  including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency,\n                  psychiatric and other conditions, which could interfere with the interpretation\n                  of the trial results or compromise the health of the volunteers\n\n               3. Any clinically significant laboratory abnormalities on screened blood samples\n                  beyond the normal range, as defined at the clinical trial site\n\n               4. Enrolment in any other clinical trial during the whole trial period\n\n               5. Intake of chronic medication, especially immunosuppressive agents (steroids,\n                  immunomodulating or immunosuppressive drugs) during the thirteen weeks preceding\n                  the screening visit or during the trial period except topical and inhaled\n                  steroids\n\n               6. Volunteers unable to be closely followed for social, geographic or psychological\n                  reasons\n\n               7. Previous history of drug or alcohol abuse interfering with normal social\n                  function during a period of one year prior to enrolment in the study\n\n               8. Known hypersensitivity to any of the vaccine components (adjuvant or peptide) or\n                  to any of the control vaccine components\n\n               9. Vaccination OR infusion of gammaglobulins from four (4) weeks prior to the first\n                  vaccination and up to six (6) weeks after the third vaccination\n\n              10. Previous vaccination with the control vaccine\n\n              11. Positive HIV, HCV test or HBVsAg positive\n\n              12. Malaria parasite positivity by microscopy and/or RDT\n\n              13. Having had a history of confirmed malaria episode in the last five year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949909", 
            "org_study_id": "P27A_1_13"
        }, 
        "intervention": {
            "arm_group_label": [
                "Alhydrogel", 
                "GLA-SE"
            ], 
            "intervention_name": "P27A vaccine candidate", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Aluminum Hydroxide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "plasmodium falciparum", 
            "long synthetic peptide", 
            "antibody", 
            "T cell", 
            "cytokine", 
            "vaccine", 
            "safety", 
            "phase 1"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "link": {
            "description": "European Vaccine Initiative", 
            "url": "http://www.euvaccine.eu"
        }, 
        "location": [
            {
                "contact": {
                    "email": "gregoire.wuerzner@chuv.ch", 
                    "last_name": "Gr\u00e9goire Wuerzner, MD", 
                    "phone": "+41 079 556 19 73"
                }, 
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "1011"
                    }, 
                    "name": "CHUV CRC"
                }, 
                "investigator": [
                    {
                        "last_name": "Olfa Karoui, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Fran\u00e7ois Spertini, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sshekalaghe@ihi.or.tz", 
                    "last_name": "Seif Shekalaghe, MD", 
                    "phone": "+255 686 997 713"
                }, 
                "facility": {
                    "address": {
                        "city": "Bagamoyo", 
                        "country": "Tanzania"
                    }, 
                    "name": "Bagamoyo Clinical Trial Unit (BCTU)"
                }, 
                "investigator": {
                    "last_name": "Seif Shekalaghe, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Switzerland", 
                "Tanzania"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A With Alhydrogel\u00ae Or GLA-SE As Adjuvant: A Staggered, Antigen And Adjuvant Dose-Finding, Randomized, Multi-Centre Phase Ia/Ib Trial", 
        "other_outcome": [
            {
                "description": "The humoral immune response quality will be assessed by measuring P27A specific antibodies IgG1, IgG2, IgG3, IgG4 subclasses by ELISA on samples obtained in all volunteers at day 0, week 8, week 12, week 26 and week 34.", 
                "measure": "Exploratory outcome measure: humoral response", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }, 
            {
                "description": "The cellular immune response quality in all volunteers will be assessed by intracellular cytokine staining (ICS) for cytokines IL-2, TNF \u03b1, IFN \u03b3 and IL-10  in proliferating Carboxyfluorescein diacetate succinimidyl ester (CFSE) loaded CD3, CD4, and CD8 cells at day 0 and week 12 and 26.", 
                "measure": "Exploratory outcome measure: cytokine production (ICS)", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }, 
            {
                "description": "The functional humoral immune response will by ADCI in the GLA-SE and the Alhydrogel\u00ae group with the highest response, at day 0 and at an optimal time-point post vaccination.", 
                "measure": "Exploratory outcome measure : antibody dependent cell cytotoxicity (ADCI)", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }
        ], 
        "overall_contact": {
            "email": "francois.spertini@yahoo.fr", 
            "last_name": "Fran\u00e7ois Spertini, MD", 
            "phone": "+41 21 314 0799"
        }, 
        "overall_contact_backup": {
            "email": "blaise.genton@chuv.ch", 
            "last_name": "Blaise Genton, MD", 
            "phone": "+41 79 556 58 68"
        }, 
        "overall_official": [
            {
                "affiliation": "Centre Hospitalier Universitaire Vaudois (CHUV)", 
                "last_name": "Fran\u00e7ois Spertini, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Bagamoyo Research and Training Center", 
                "last_name": "Salim Abdulla, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The safety profile will be assessed on the basis of immediate local and systemic reactogenicity measured from Day 0 to Day 28 after each vaccination", 
            "measure": "To evaluate the safety of P27A with Alhydrogel or GLA-SE as adjuvant, in healthy European adults not previously exposed to the parasite Plasmodium falciparum and in healthy African adults previously exposed to the parasite", 
            "safety_issue": "Yes", 
            "time_frame": "15 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949909"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centre Hospitalier Universitaire Vaudois", 
            "investigator_full_name": "Fran\u00e7ois Spertini", 
            "investigator_title": "Dr", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The humoral response to the vaccine antigen will be assessed in all volunteers by ELISA to measure the level of total antigen specific IgG.", 
                "measure": "Assessment of the humoral immune response to the vaccine antigen", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }, 
            {
                "description": "The cellular immune response will be assessed in all volunteers by measuring the T cell proliferation and cytokine production following in vitro stimulation with the vaccine antigen (by Luminex on cell culture supernatant after in vitro stimulation of PBMC for 6 days with the P27A peptide). Proliferation of carboxyfluorescein diacetate succinimidyl ester (CFSE) loaded CD3+ CD4+ and CD3+CD8+ T cells will be assayed by using polychromatic flow cytometry.", 
                "measure": "Assessment of the cellular immune response to the vaccine antigen", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }
        ], 
        "source": "Centre Hospitalier Universitaire Vaudois", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "European Vaccine Initiative (EVI), Heidelberg, Germany", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "European & Developing Countries Clinical Trials Partnership (EDCTP)", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire Vaudois", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}